您的购物车当前为空
CLK-IN-T3 是 CLK1、CLK2 和 CLK3 的抑制剂,IC50 为 0.67、15 和 110 nM。 CLK-IN-T3 具有抗癌活性。


为众多的药物研发团队赋能,
让新药发现更简单!
CLK-IN-T3 是 CLK1、CLK2 和 CLK3 的抑制剂,IC50 为 0.67、15 和 110 nM。 CLK-IN-T3 具有抗癌活性。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 363 | In Stock | |
| 5 mg | ¥ 868 | In Stock | |
| 10 mg | ¥ 1,480 | In Stock | |
| 25 mg | ¥ 3,380 | In Stock | |
| 50 mg | ¥ 4,830 | In Stock | |
| 100 mg | ¥ 6,730 | In Stock | |
| 200 mg | ¥ 8,890 | In Stock |
CLK-IN-T3 相关产品
| 产品描述 | CLK-IN-T3 is an inhibitor of CLK1, CLK2, and CLK3 with IC50s of 0.67, 15, and 110 nM. CLK-IN-T3 exhibits anti-cancer activity. |
| 靶点活性 | DYRK1A:260 nM, CLK2:15 nM, CLK1:0.67 nM, CLK3:110 nM, DYRK1B:230 nM |
| 体外活性 | CLK-IN-T3 (0.5, 1.0 μM) decreases the phosphorylation of CLK-targeted SR proteins and CLK proteins increase slightly. CLK-IN-T3 (0.1, 0.5, 1.0, 5.0, 10.0 µM) results in mild cell cycle arrest at the G2/M boundary with a long-duration of 24 h. CLK-IN-T3 inhibits DYRK1A and DYRK1B with IC50s of 260 and 230 nM[1]. |
| 分子量 | 482.58 |
| 分子式 | C28H30N6O2 |
| CAS No. | 2109805-56-1 |
| Smiles | CN1CCN(CC1)C(=O)C(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-c1ccncc1 |
| 密度 | 1.25 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||
| 溶解度信息 | DMSO: 4.5 mg/mL (9.32 mM), Sonication and heating are recommended. | |||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.07 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||
溶液配制表 | ||||||||||||||||
DMSO
| ||||||||||||||||
评论内容